{"id":356329,"date":"2025-08-29T06:15:54","date_gmt":"2025-08-29T06:15:54","guid":{"rendered":"https:\/\/pocketoption.com\/blog\/how-to-buy-vaxcyte\/"},"modified":"2025-08-29T06:15:54","modified_gmt":"2025-08-29T06:15:54","slug":"how-to-buy-vaxcyte","status":"publish","type":"post","link":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-vaxcyte\/","title":{"rendered":"Vaxcyte, Inc. (PCVX) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Vaxcyte, Inc. (PCVX) Hisse Senedi Yat\u0131r\u0131m\u0131"},"content":{"rendered":"<div id=\"root\"><div id=\"wrap-img-root\">text<\/div><\/div>","protected":false},"excerpt":{"rendered":"<p>text<\/p>\n","protected":false},"author":129,"featured_media":334027,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[12837],"tags":[40],"class_list":["post-356329","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-signal","tag-signal"],"acf":{"h1":"Vaxcyte, Inc. (PCVX) Hisseleri Nas\u0131l Al\u0131n\u0131r - Vaxcyte, Inc. (PCVX) Hisse Senedi Yat\u0131r\u0131m\u0131","h1_source":{"label":"H1","type":"text","formatted_value":"Vaxcyte, Inc. (PCVX) Hisseleri Nas\u0131l Al\u0131n\u0131r - Vaxcyte, Inc. (PCVX) Hisse Senedi Yat\u0131r\u0131m\u0131"},"description":"Bu yenilik\u00e7i a\u015f\u0131 \u015firketi i\u00e7in g\u00fcncel fiyat analizi, risk de\u011ferlendirmesi ve yat\u0131r\u0131m stratejileri ile Vaxcyte, Inc. (PCVX) hisselerinin nas\u0131l al\u0131naca\u011f\u0131n\u0131 \u00f6\u011frenin.","description_source":{"label":"Description","type":"textarea","formatted_value":"Bu yenilik\u00e7i a\u015f\u0131 \u015firketi i\u00e7in g\u00fcncel fiyat analizi, risk de\u011ferlendirmesi ve yat\u0131r\u0131m stratejileri ile Vaxcyte, Inc. (PCVX) hisselerinin nas\u0131l al\u0131naca\u011f\u0131n\u0131 \u00f6\u011frenin."},"intro":"A\u015f\u0131 teknolojisinin gelece\u011fine yat\u0131r\u0131m yapmay\u0131 m\u0131 d\u00fc\u015f\u00fcn\u00fcyorsunuz? Vaxcyte, Inc. \u015fu anda biyoteknolojideki en heyecan verici f\u0131rsatlardan birini temsil ediyor. Klinik a\u015famas\u0131ndaki bu \u015firket, bakteriyel enfeksiyonlarla m\u00fccadelede \u00e7\u0131\u011f\u0131r a\u00e7an a\u015f\u0131 platformlar\u0131yla devrim yarat\u0131yor. PCVX hisselerine yat\u0131r\u0131m yaparken bilmeniz gereken her \u015feyi\u2014g\u00fcncel performanstan uzun vadeli potansiyele kadar\u2014anlataca\u011f\u0131z.","intro_source":{"label":"Intro","type":"text","formatted_value":"A\u015f\u0131 teknolojisinin gelece\u011fine yat\u0131r\u0131m yapmay\u0131 m\u0131 d\u00fc\u015f\u00fcn\u00fcyorsunuz? Vaxcyte, Inc. \u015fu anda biyoteknolojideki en heyecan verici f\u0131rsatlardan birini temsil ediyor. Klinik a\u015famas\u0131ndaki bu \u015firket, bakteriyel enfeksiyonlarla m\u00fccadelede \u00e7\u0131\u011f\u0131r a\u00e7an a\u015f\u0131 platformlar\u0131yla devrim yarat\u0131yor. PCVX hisselerine yat\u0131r\u0131m yaparken bilmeniz gereken her \u015feyi\u2014g\u00fcncel performanstan uzun vadeli potansiyele kadar\u2014anlataca\u011f\u0131z."},"body_html":"<h2>\ud83d\udcc8 Vaxcyte Hissesi: G\u00fcncel Fiyat ve Kritik Tarihler<\/h2> <p>29 A\u011fustos 2025 itibar\u0131yla, Vaxcyte, Inc. (PCVX) NASDAQ'da <strong>30,55 $<\/strong> seviyesinde i\u015flem g\u00f6r\u00fcyor. Takviminize not edin: <strong>4 Kas\u0131m 2025<\/strong> kesinlikle kritik\u2014Vaxcyte'nin 3. \u00e7eyrek kazan\u00e7 raporunu yay\u0131nlayaca\u011f\u0131 tarih. Tarihsel olarak, bu a\u00e7\u0131klamalar b\u00fcy\u00fck fiyat hareketlerine yol a\u00e7t\u0131.<\/p> <h3>Kazan\u00e7lar\u0131n Etki Analizi<\/h3> <p>6 A\u011fustos 2025 kazan\u00e7 raporu zamanlaman\u0131n neden \u00f6nemli oldu\u011funu g\u00f6sterdi. Vaxcyte, gelir olmadan 166,6 milyon $ net zarar bildirdi, ancak hisse senedi nispeten sabit kald\u0131 \u00e7\u00fcnk\u00fc yat\u0131r\u0131mc\u0131lar bunun klinik a\u015famadaki bir \u015firketten beklenen bir durum oldu\u011funu d\u00fc\u015f\u00fcnd\u00fc <a href=\"https:\/\/www.stocktitan.net\/news\/PCVX\/vaxcyte-reports-second-quarter-2025-financial-results-and-provides-9l3y1y5unk80.html\">StockTitan<\/a>. As\u0131l hikaye, VAX-31 programlar\u0131n\u0131n Faz 3 denemelerine ilerlemesiydi.<\/p> <p>Son kazan\u00e7lar\u0131n hisse senedini nas\u0131l etkiledi\u011fi a\u015fa\u011f\u0131da g\u00f6sterilmi\u015ftir:<\/p> <table> <thead> <tr><th>Tarih<\/th><th>Olay<\/th><th>Haber \u00d6ncesi Fiyat<\/th><th>Haber Sonras\u0131 De\u011fi\u015fim<\/th><\/tr> <\/thead> <tbody> <tr><td>6 A\u011fu 2025<\/td><td>2. \u00c7eyrek Kazan\u00e7lar\u0131<\/td><td>31,20 $<\/td><td>%2,1 D\u00fc\u015f\u00fc\u015f (Sabit)<\/td><\/tr> <tr><td>23 May\u0131s 2025<\/td><td>Faz II Sonu\u00e7lar\u0131<\/td><td>69,46 $<\/td><td>%45 D\u00fc\u015f\u00fc\u015f (Bir G\u00fcn)<\/td><\/tr> <tr><td>28 Mar 2025<\/td><td>Deneme Verileri<\/td><td>72,10 $<\/td><td>%4,2 D\u00fc\u015f\u00fc\u015f (\u00d6n Sat\u0131\u015f)<\/td><\/tr> <\/tbody> <\/table> <p>May\u0131s ay\u0131ndaki \u00e7\u00f6k\u00fc\u015f bize ac\u0131 bir ders verdi: denemeler teknik olarak hedeflere ula\u015fsa bile, yat\u0131r\u0131mc\u0131 beklentileri y\u0131k\u0131c\u0131 sat\u0131\u015flara neden olabilir <a href=\"https:\/\/www.clinicaltrialsarena.com\/news\/vaxcyte-ipd-vaccine-phase-ii-infant-stock-sinks\/\">Clinical Trials Arena<\/a>.<\/p> [cta_green text=\"Ticarete Ba\u015fla\"]<h2>\ud83d\udcca 6 Ayl\u0131k Fiyat Yolculu\u011fu: Dalgalarla Dolu Bir S\u00fcr\u00fc\u015f<\/h2> <p>Vaxcyte hisseleri son alt\u0131 ayda a\u015f\u0131r\u0131 volatilite ya\u015fad\u0131 ve Ocak ay\u0131 zirvesinden yakla\u015f\u0131k <strong>%61<\/strong> d\u00fc\u015ft\u00fc:<\/p> <p><strong>Ocak 2025<\/strong>: 93,77 $ (zirve iyimserli\u011fi)<br\/> <strong>Mart 2025<\/strong>: 69,46 $ (deneme sonu\u00e7lar\u0131 \u00f6ncesi)<br\/> <strong>May\u0131s 2025<\/strong>: 32,54 $ (deneme sonras\u0131 \u00e7\u00f6k\u00fc\u015f)<br\/> <strong>A\u011fustos 2025<\/strong>: 30,55 $ (g\u00fcncel stabilizasyon)<\/p> <p>Bu dramatik d\u00fc\u015f\u00fc\u015f, klinik a\u015famadaki biyoteknoloji yat\u0131r\u0131mlar\u0131n\u0131n y\u00fcksek risk do\u011fas\u0131n\u0131 yans\u0131t\u0131yor. Hisse senedi 30 $ civar\u0131nda bir destek seviyesi bulmu\u015f gibi g\u00f6r\u00fcn\u00fcyor <a href=\"https:\/\/stockanalysis.com\/stocks\/pcvx\/\">StockAnalysis<\/a>.<\/p> <h2>\ud83d\udd2e Fiyat Tahmini: 2025-2030 G\u00f6r\u00fcn\u00fcm\u00fc<\/h2> <p>Analistlerin g\u00f6r\u00fc\u015fleri ve klinik ilerlemeye dayanarak, beklenenler \u015funlard\u0131r:<\/p> <p><strong>2025 Y\u0131l Sonu<\/strong>: 40-50 $ (Faz 3 ba\u015flang\u0131c\u0131 art\u0131\u015f\u0131) \u2192 <strong>AL<\/strong><br\/> <strong>2026<\/strong>: 90-110 $ (pozitif ara veri potansiyeli)<br\/> <strong>2028<\/strong>: 120-150 $ (d\u00fczenleyici ba\u015fvuru a\u015famas\u0131)<br\/> <strong>2030<\/strong>: 180-220 $ (potansiyel ticarile\u015fme)<\/p> <p>Analistler, ortalama fiyat hedefi olarak <strong>136,50 $<\/strong> ile b\u00fcy\u00fck bir iyimserlik s\u00fcrd\u00fcr\u00fcyor\u2014bu, mevcut seviyelerden %343 y\u00fckseli\u015f anlam\u0131na geliyor <a href=\"https:\/\/www.marketbeat.com\/stocks\/NASDAQ\/PCVX\/forecast\/\">MarketBeat<\/a>. On bir analistten on tanesi \"Al\" veya \"G\u00fc\u00e7l\u00fc Al\" derecelendirmesi veriyor.<\/p> <h2>\u26a0\ufe0f Temel Riskler ve Olumlu \u0130\u015faretler<\/h2> <h3>Dikkate Al\u0131nmas\u0131 Gereken Riskler<\/h3> <ul> <li><strong>Klinik ba\u015far\u0131s\u0131zl\u0131k riski<\/strong>: May\u0131s 2025'teki %45'lik \u00e7\u00f6k\u00fc\u015f, k\u0131smi deneme sonu\u00e7lar\u0131n\u0131n ne kadar y\u0131k\u0131c\u0131 olabilece\u011fini g\u00f6sterdi<\/li> <li><strong>D\u00fczenleyici belirsizlik<\/strong>: FDA yetkililerinin istifalar\u0131 \u00f6ng\u00f6r\u00fclemez zaman \u00e7izelgeleri yarat\u0131yor<\/li> <li><strong>Nakit yak\u0131m\u0131<\/strong>: Hen\u00fcz gelir olmadan \u00e7eyreklik 166,6 milyon $ zarar<\/li> <li><strong>Rekabet<\/strong>: Pfizer'\u0131n yerle\u015fik a\u015f\u0131lar\u0131 piyasaya hakim<\/li> <\/ul> <h3>2025 \u0130\u00e7in Ye\u015fil I\u015f\u0131klar<\/h3> <ul> <li><strong>Faz 3 ilerlemesi<\/strong>: VAX-31, 2025 4. \u00e7eyrekte kritik denemeler i\u00e7in onayland\u0131<\/li> <li><strong>At\u0131l\u0131m tan\u0131m\u0131<\/strong>: FDA, bu stat\u00fcy\u00fc zat\u00fcrre \u00f6nlemeyi de kapsayacak \u015fekilde geni\u015fletti<\/li> <li><strong>G\u00fc\u00e7l\u00fc nakit pozisyonu<\/strong>: 2,8 milyar $ nakit, 2028 ortalar\u0131na kadar finansman sa\u011fl\u0131yor<\/li> <li><strong>Analist g\u00fcveni<\/strong>: %93 al\u0131m \u00f6nerisi ve y\u00fcksek y\u00fckseli\u015f hedefleri<\/li> <\/ul> <h2>\ud83d\udee1\ufe0f Yeni Ba\u015flayan Bir T\u00fcccar Bug\u00fcn Ne Yapmal\u0131?<\/h2> <ol> <li><strong>Dolar-maliyet ortalamas\u0131<\/strong>: Piyasay\u0131 zamanlamaya \u00e7al\u0131\u015fmak yerine d\u00fczenli k\u00fc\u00e7\u00fck yat\u0131r\u0131mlar yap\u0131n<\/li> <li><strong>Stop-loss belirleyin<\/strong>: Tek seferde %45'lik bir d\u00fc\u015f\u00fc\u015ften korunmak i\u00e7in<\/li> <li><strong>4 Kas\u0131m'\u0131 izleyin<\/strong>: Kazan\u00e7lar bir sonraki b\u00fcy\u00fck kataliz\u00f6r\u00fc sa\u011flayabilir<\/li> <li><strong>\u00c7e\u015fitlendirin<\/strong>: Portf\u00f6y\u00fcn\u00fcz\u00fcn %5'inden fazlas\u0131n\u0131 tek bir biyotek hisse senedine koymay\u0131n<\/li> <\/ol> <p>Mizahi bir yorum: \"PCVX ticareti, parlak bir bilim insan\u0131yla \u00e7\u0131kmak gibidir\u2014inan\u0131lmaz potansiyel ama deneyler planland\u0131\u011f\u0131 gibi gitmedi\u011finde dramatik ruh hali de\u011fi\u015fimlerine e\u011filimli!\"<\/p> <h2>\u2705 Vaxcyte, Inc. (PCVX) Hisseleri Nas\u0131l Al\u0131n\u0131r - Ad\u0131m Ad\u0131m<\/h2> <table> <thead> <tr><th>Ad\u0131m<\/th><th>\u0130\u015flem<\/th><th>Neden \u00d6nemli<\/th><\/tr> <\/thead> <tbody> <tr><td>1<\/td><td>Bir ticaret platformu se\u00e7in<\/td><td>NASDAQ hisseleri ve kesirli paylar sunmas\u0131na dikkat edin<\/td><\/tr> <tr><td>2<\/td><td>Do\u011frulamay\u0131 tamamlay\u0131n<\/td><td>H\u0131zl\u0131 hesap a\u00e7\u0131l\u0131\u015f\u0131 i\u00e7in resmi kimlik haz\u0131r bulundurun<\/td><\/tr> <tr><td>3<\/td><td>Hesab\u0131n\u0131z\u0131 fonlay\u0131n<\/td><td>Risk almaya haz\u0131r oldu\u011funuz bir miktarla ba\u015flay\u0131n<\/td><\/tr> <tr><td>4<\/td><td>\"PCVX\" aramas\u0131 yap\u0131n<\/td><td>Sadece \"Vaxcyte\" de\u011fil, borsa sembol\u00fcn\u00fc kullan\u0131n<\/td><\/tr> <tr><td>5<\/td><td>Limit emirleri kullan\u0131n<\/td><td>Fazla \u00f6deme yapmamak i\u00e7in maksimum al\u0131\u015f fiyat\u0131n\u0131z\u0131 belirleyin<\/td><\/tr> <tr><td>6<\/td><td>Emir detaylar\u0131n\u0131 g\u00f6zden ge\u00e7irin<\/td><td>Komisyon \u00fccretlerini kontrol edin\u2014%1'in alt\u0131nda hedefleyin<\/td><\/tr> <tr><td>7<\/td><td>Al\u0131m\u0131 onaylay\u0131n<\/td><td>Art\u0131k yenilik\u00e7i bir a\u015f\u0131 \u015firketinin bir par\u00e7as\u0131na sahipsiniz<\/td><\/tr> <tr><td>8<\/td><td>Fiyat uyar\u0131lar\u0131 kurun<\/td><td>B\u00fcy\u00fck fiyat hareketlerinden haberdar olun<\/td><\/tr> <tr><td>9<\/td><td>Haberleri takip edin<\/td><td>Klinik deneme g\u00fcncellemeleri ve FDA kararlar\u0131n\u0131 izleyin<\/td><\/tr> <tr><td>10<\/td><td>D\u00fczenli olarak g\u00f6zden ge\u00e7irin<\/td><td>Biyoteknoloji aktif takip gerektirir, unutup b\u0131rakmak olmaz<\/td><\/tr> <\/tbody> <\/table> <h2>\ud83d\udca1 Neden Pocket Option Yeni Yat\u0131r\u0131mc\u0131lar \u0130\u00e7in Uygun?<\/h2> <p>Yat\u0131r\u0131m yolculu\u011funa yeni ba\u015flayanlar i\u00e7in Pocket Option, PCVX gibi hisselerde i\u015flem yapmak i\u00e7in birka\u00e7 avantaj sunar:<\/p> <ul> <li><strong>Minimum depozito sadece 5 $<\/strong>\u2014stratejileri d\u00fc\u015f\u00fck riskle test etmek i\u00e7in ideal<\/li> <li><strong>1 dakikal\u0131k KYC s\u00fcreci<\/strong>\u2014herhangi bir kimlik belgesini y\u00fckleyin ve hemen i\u015flem yapmaya ba\u015flay\u0131n<\/li> <li><strong>100'den fazla para \u00e7ekme y\u00f6ntemi<\/strong>\u2014kripto paralardan e-c\u00fczdanlara ve banka kartlar\u0131na kadar<\/li> <li><strong>Kesirli hisse senetleri mevcut<\/strong>\u2014PCVX gibi pahal\u0131 hisselerin par\u00e7alar\u0131n\u0131 tam hisse almadan sat\u0131n al\u0131n<\/li> <\/ul> <p>Platformun d\u00fc\u015f\u00fck giri\u015f engeli, b\u00fcy\u00fck sermaye taahh\u00fcd\u00fc olmadan y\u00fcksek potansiyelli biyotek hisselerine maruz kalmak isteyen yeni ba\u015flayanlar i\u00e7in idealdir.<\/p> <h2>\ud83c\udf0d 2025'te Vaxcyte: A\u015f\u0131 \u0130novasyon Lideri<\/h2> <p>Vaxcyte, yeni nesil a\u015f\u0131 teknolojisinin \u00f6n saflar\u0131nda yer al\u0131yor. Kendi XpressCF\u2122 platformlar\u0131n\u0131 kullanarak, bakteriyel enfeksiyonlar\u0131 \u00f6nlemede devrim yaratabilecek konjuge a\u015f\u0131lar geli\u015ftiriyorlar <a href=\"https:\/\/stockanalysis.com\/stocks\/pcvx\/company\/\">StockAnalysis<\/a>.<\/p> <p>\u015eirketin \u00f6nc\u00fc aday\u0131 VAX-24, 24 pn\u00f6mokok bakteri su\u015funu hedeflerken, VAX-31 bunu 31 su\u015fa geni\u015fletiyor\u2014mevcut a\u015f\u0131lardan daha geni\u015f koruma sunma potansiyeline sahip. 414 \u00e7al\u0131\u015fan\u0131 ve Kaliforniya, San Carlos'taki genel merkezi ile Vaxcyte, Amerikan inovasyonunun en iyisini temsil ediyor.<\/p> <p><strong>\u0130lgin\u00e7 Bilgi<\/strong>: 2025'te Vaxcyte'nin FDA At\u0131l\u0131m Tedavisi tan\u0131m\u0131, zat\u00fcrre \u00f6nlemeyi de kapsayacak \u015fekilde geni\u015fletildi\u2014bu, VAX-31 a\u015f\u0131 adaylar\u0131n\u0131n potansiyel \u00f6nemini vurgulayan nadir bir d\u00fczenleyici ba\u015far\u0131d\u0131r <a href=\"https:\/\/www.stocktitan.net\/news\/PCVX\/vaxcyte-reports-second-quarter-2025-financial-results-and-provides-9l3y1y5unk80.html\">StockTitan<\/a>. Bu, onlar\u0131 biyoteknoloji yenilik\u00e7ileri aras\u0131nda se\u00e7kin bir konuma yerle\u015ftiriyor.<\/p>","body_html_source":{"label":"Body HTML","type":"wysiwyg","formatted_value":"<h2>\ud83d\udcc8 Vaxcyte Hissesi: G\u00fcncel Fiyat ve Kritik Tarihler<\/h2>\n<p>29 A\u011fustos 2025 itibar\u0131yla, Vaxcyte, Inc. (PCVX) NASDAQ&#8217;da <strong>30,55 $<\/strong> seviyesinde i\u015flem g\u00f6r\u00fcyor. Takviminize not edin: <strong>4 Kas\u0131m 2025<\/strong> kesinlikle kritik\u2014Vaxcyte&#8217;nin 3. \u00e7eyrek kazan\u00e7 raporunu yay\u0131nlayaca\u011f\u0131 tarih. Tarihsel olarak, bu a\u00e7\u0131klamalar b\u00fcy\u00fck fiyat hareketlerine yol a\u00e7t\u0131.<\/p>\n<h3>Kazan\u00e7lar\u0131n Etki Analizi<\/h3>\n<p>6 A\u011fustos 2025 kazan\u00e7 raporu zamanlaman\u0131n neden \u00f6nemli oldu\u011funu g\u00f6sterdi. Vaxcyte, gelir olmadan 166,6 milyon $ net zarar bildirdi, ancak hisse senedi nispeten sabit kald\u0131 \u00e7\u00fcnk\u00fc yat\u0131r\u0131mc\u0131lar bunun klinik a\u015famadaki bir \u015firketten beklenen bir durum oldu\u011funu d\u00fc\u015f\u00fcnd\u00fc <a href=\"https:\/\/www.stocktitan.net\/news\/PCVX\/vaxcyte-reports-second-quarter-2025-financial-results-and-provides-9l3y1y5unk80.html\">StockTitan<\/a>. As\u0131l hikaye, VAX-31 programlar\u0131n\u0131n Faz 3 denemelerine ilerlemesiydi.<\/p>\n<p>Son kazan\u00e7lar\u0131n hisse senedini nas\u0131l etkiledi\u011fi a\u015fa\u011f\u0131da g\u00f6sterilmi\u015ftir:<\/p>\n<table>\n<thead>\n<tr>\n<th>Tarih<\/th>\n<th>Olay<\/th>\n<th>Haber \u00d6ncesi Fiyat<\/th>\n<th>Haber Sonras\u0131 De\u011fi\u015fim<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>6 A\u011fu 2025<\/td>\n<td>2. \u00c7eyrek Kazan\u00e7lar\u0131<\/td>\n<td>31,20 $<\/td>\n<td>%2,1 D\u00fc\u015f\u00fc\u015f (Sabit)<\/td>\n<\/tr>\n<tr>\n<td>23 May\u0131s 2025<\/td>\n<td>Faz II Sonu\u00e7lar\u0131<\/td>\n<td>69,46 $<\/td>\n<td>%45 D\u00fc\u015f\u00fc\u015f (Bir G\u00fcn)<\/td>\n<\/tr>\n<tr>\n<td>28 Mar 2025<\/td>\n<td>Deneme Verileri<\/td>\n<td>72,10 $<\/td>\n<td>%4,2 D\u00fc\u015f\u00fc\u015f (\u00d6n Sat\u0131\u015f)<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>May\u0131s ay\u0131ndaki \u00e7\u00f6k\u00fc\u015f bize ac\u0131 bir ders verdi: denemeler teknik olarak hedeflere ula\u015fsa bile, yat\u0131r\u0131mc\u0131 beklentileri y\u0131k\u0131c\u0131 sat\u0131\u015flara neden olabilir <a href=\"https:\/\/www.clinicaltrialsarena.com\/news\/vaxcyte-ipd-vaccine-phase-ii-infant-stock-sinks\/\">Clinical Trials Arena<\/a>.<\/p>\n<div class=\"po-container po-container_width_article\">\n   <div class=\"po-cta-green__wrap\">\n      <a href=\"https:\/\/pocketoption.com\/tr\/register\/\" class=\"po-cta-green\">Ticarete Ba\u015fla\n         <span class=\"po-cta-green__icon\">\n            <svg width=\"24\" height=\"24\" fill=\"none\" aria-hidden=\"true\">\n               <use href=\"#svg-arrow-cta\"><\/use>\n            <\/svg>\n         <\/span>\n      <\/a>\n   <\/div>\n<\/div>\n<h2>\ud83d\udcca 6 Ayl\u0131k Fiyat Yolculu\u011fu: Dalgalarla Dolu Bir S\u00fcr\u00fc\u015f<\/h2>\n<p>Vaxcyte hisseleri son alt\u0131 ayda a\u015f\u0131r\u0131 volatilite ya\u015fad\u0131 ve Ocak ay\u0131 zirvesinden yakla\u015f\u0131k <strong>%61<\/strong> d\u00fc\u015ft\u00fc:<\/p>\n<p><strong>Ocak 2025<\/strong>: 93,77 $ (zirve iyimserli\u011fi)<br \/> <strong>Mart 2025<\/strong>: 69,46 $ (deneme sonu\u00e7lar\u0131 \u00f6ncesi)<br \/> <strong>May\u0131s 2025<\/strong>: 32,54 $ (deneme sonras\u0131 \u00e7\u00f6k\u00fc\u015f)<br \/> <strong>A\u011fustos 2025<\/strong>: 30,55 $ (g\u00fcncel stabilizasyon)<\/p>\n<p>Bu dramatik d\u00fc\u015f\u00fc\u015f, klinik a\u015famadaki biyoteknoloji yat\u0131r\u0131mlar\u0131n\u0131n y\u00fcksek risk do\u011fas\u0131n\u0131 yans\u0131t\u0131yor. Hisse senedi 30 $ civar\u0131nda bir destek seviyesi bulmu\u015f gibi g\u00f6r\u00fcn\u00fcyor <a href=\"https:\/\/stockanalysis.com\/stocks\/pcvx\/\">StockAnalysis<\/a>.<\/p>\n<h2>\ud83d\udd2e Fiyat Tahmini: 2025-2030 G\u00f6r\u00fcn\u00fcm\u00fc<\/h2>\n<p>Analistlerin g\u00f6r\u00fc\u015fleri ve klinik ilerlemeye dayanarak, beklenenler \u015funlard\u0131r:<\/p>\n<p><strong>2025 Y\u0131l Sonu<\/strong>: 40-50 $ (Faz 3 ba\u015flang\u0131c\u0131 art\u0131\u015f\u0131) \u2192 <strong>AL<\/strong><br \/> <strong>2026<\/strong>: 90-110 $ (pozitif ara veri potansiyeli)<br \/> <strong>2028<\/strong>: 120-150 $ (d\u00fczenleyici ba\u015fvuru a\u015famas\u0131)<br \/> <strong>2030<\/strong>: 180-220 $ (potansiyel ticarile\u015fme)<\/p>\n<p>Analistler, ortalama fiyat hedefi olarak <strong>136,50 $<\/strong> ile b\u00fcy\u00fck bir iyimserlik s\u00fcrd\u00fcr\u00fcyor\u2014bu, mevcut seviyelerden %343 y\u00fckseli\u015f anlam\u0131na geliyor <a href=\"https:\/\/www.marketbeat.com\/stocks\/NASDAQ\/PCVX\/forecast\/\">MarketBeat<\/a>. On bir analistten on tanesi &#8220;Al&#8221; veya &#8220;G\u00fc\u00e7l\u00fc Al&#8221; derecelendirmesi veriyor.<\/p>\n<h2>\u26a0\ufe0f Temel Riskler ve Olumlu \u0130\u015faretler<\/h2>\n<h3>Dikkate Al\u0131nmas\u0131 Gereken Riskler<\/h3>\n<ul>\n<li><strong>Klinik ba\u015far\u0131s\u0131zl\u0131k riski<\/strong>: May\u0131s 2025&#8217;teki %45&#8217;lik \u00e7\u00f6k\u00fc\u015f, k\u0131smi deneme sonu\u00e7lar\u0131n\u0131n ne kadar y\u0131k\u0131c\u0131 olabilece\u011fini g\u00f6sterdi<\/li>\n<li><strong>D\u00fczenleyici belirsizlik<\/strong>: FDA yetkililerinin istifalar\u0131 \u00f6ng\u00f6r\u00fclemez zaman \u00e7izelgeleri yarat\u0131yor<\/li>\n<li><strong>Nakit yak\u0131m\u0131<\/strong>: Hen\u00fcz gelir olmadan \u00e7eyreklik 166,6 milyon $ zarar<\/li>\n<li><strong>Rekabet<\/strong>: Pfizer&#8217;\u0131n yerle\u015fik a\u015f\u0131lar\u0131 piyasaya hakim<\/li>\n<\/ul>\n<h3>2025 \u0130\u00e7in Ye\u015fil I\u015f\u0131klar<\/h3>\n<ul>\n<li><strong>Faz 3 ilerlemesi<\/strong>: VAX-31, 2025 4. \u00e7eyrekte kritik denemeler i\u00e7in onayland\u0131<\/li>\n<li><strong>At\u0131l\u0131m tan\u0131m\u0131<\/strong>: FDA, bu stat\u00fcy\u00fc zat\u00fcrre \u00f6nlemeyi de kapsayacak \u015fekilde geni\u015fletti<\/li>\n<li><strong>G\u00fc\u00e7l\u00fc nakit pozisyonu<\/strong>: 2,8 milyar $ nakit, 2028 ortalar\u0131na kadar finansman sa\u011fl\u0131yor<\/li>\n<li><strong>Analist g\u00fcveni<\/strong>: %93 al\u0131m \u00f6nerisi ve y\u00fcksek y\u00fckseli\u015f hedefleri<\/li>\n<\/ul>\n<h2>\ud83d\udee1\ufe0f Yeni Ba\u015flayan Bir T\u00fcccar Bug\u00fcn Ne Yapmal\u0131?<\/h2>\n<ol>\n<li><strong>Dolar-maliyet ortalamas\u0131<\/strong>: Piyasay\u0131 zamanlamaya \u00e7al\u0131\u015fmak yerine d\u00fczenli k\u00fc\u00e7\u00fck yat\u0131r\u0131mlar yap\u0131n<\/li>\n<li><strong>Stop-loss belirleyin<\/strong>: Tek seferde %45&#8217;lik bir d\u00fc\u015f\u00fc\u015ften korunmak i\u00e7in<\/li>\n<li><strong>4 Kas\u0131m&#8217;\u0131 izleyin<\/strong>: Kazan\u00e7lar bir sonraki b\u00fcy\u00fck kataliz\u00f6r\u00fc sa\u011flayabilir<\/li>\n<li><strong>\u00c7e\u015fitlendirin<\/strong>: Portf\u00f6y\u00fcn\u00fcz\u00fcn %5&#8217;inden fazlas\u0131n\u0131 tek bir biyotek hisse senedine koymay\u0131n<\/li>\n<\/ol>\n<p>Mizahi bir yorum: &#8220;PCVX ticareti, parlak bir bilim insan\u0131yla \u00e7\u0131kmak gibidir\u2014inan\u0131lmaz potansiyel ama deneyler planland\u0131\u011f\u0131 gibi gitmedi\u011finde dramatik ruh hali de\u011fi\u015fimlerine e\u011filimli!&#8221;<\/p>\n<h2>\u2705 Vaxcyte, Inc. (PCVX) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Ad\u0131m Ad\u0131m<\/h2>\n<table>\n<thead>\n<tr>\n<th>Ad\u0131m<\/th>\n<th>\u0130\u015flem<\/th>\n<th>Neden \u00d6nemli<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>1<\/td>\n<td>Bir ticaret platformu se\u00e7in<\/td>\n<td>NASDAQ hisseleri ve kesirli paylar sunmas\u0131na dikkat edin<\/td>\n<\/tr>\n<tr>\n<td>2<\/td>\n<td>Do\u011frulamay\u0131 tamamlay\u0131n<\/td>\n<td>H\u0131zl\u0131 hesap a\u00e7\u0131l\u0131\u015f\u0131 i\u00e7in resmi kimlik haz\u0131r bulundurun<\/td>\n<\/tr>\n<tr>\n<td>3<\/td>\n<td>Hesab\u0131n\u0131z\u0131 fonlay\u0131n<\/td>\n<td>Risk almaya haz\u0131r oldu\u011funuz bir miktarla ba\u015flay\u0131n<\/td>\n<\/tr>\n<tr>\n<td>4<\/td>\n<td>&#8220;PCVX&#8221; aramas\u0131 yap\u0131n<\/td>\n<td>Sadece &#8220;Vaxcyte&#8221; de\u011fil, borsa sembol\u00fcn\u00fc kullan\u0131n<\/td>\n<\/tr>\n<tr>\n<td>5<\/td>\n<td>Limit emirleri kullan\u0131n<\/td>\n<td>Fazla \u00f6deme yapmamak i\u00e7in maksimum al\u0131\u015f fiyat\u0131n\u0131z\u0131 belirleyin<\/td>\n<\/tr>\n<tr>\n<td>6<\/td>\n<td>Emir detaylar\u0131n\u0131 g\u00f6zden ge\u00e7irin<\/td>\n<td>Komisyon \u00fccretlerini kontrol edin\u2014%1&#8217;in alt\u0131nda hedefleyin<\/td>\n<\/tr>\n<tr>\n<td>7<\/td>\n<td>Al\u0131m\u0131 onaylay\u0131n<\/td>\n<td>Art\u0131k yenilik\u00e7i bir a\u015f\u0131 \u015firketinin bir par\u00e7as\u0131na sahipsiniz<\/td>\n<\/tr>\n<tr>\n<td>8<\/td>\n<td>Fiyat uyar\u0131lar\u0131 kurun<\/td>\n<td>B\u00fcy\u00fck fiyat hareketlerinden haberdar olun<\/td>\n<\/tr>\n<tr>\n<td>9<\/td>\n<td>Haberleri takip edin<\/td>\n<td>Klinik deneme g\u00fcncellemeleri ve FDA kararlar\u0131n\u0131 izleyin<\/td>\n<\/tr>\n<tr>\n<td>10<\/td>\n<td>D\u00fczenli olarak g\u00f6zden ge\u00e7irin<\/td>\n<td>Biyoteknoloji aktif takip gerektirir, unutup b\u0131rakmak olmaz<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h2>\ud83d\udca1 Neden Pocket Option Yeni Yat\u0131r\u0131mc\u0131lar \u0130\u00e7in Uygun?<\/h2>\n<p>Yat\u0131r\u0131m yolculu\u011funa yeni ba\u015flayanlar i\u00e7in Pocket Option, PCVX gibi hisselerde i\u015flem yapmak i\u00e7in birka\u00e7 avantaj sunar:<\/p>\n<ul>\n<li><strong>Minimum depozito sadece 5 $<\/strong>\u2014stratejileri d\u00fc\u015f\u00fck riskle test etmek i\u00e7in ideal<\/li>\n<li><strong>1 dakikal\u0131k KYC s\u00fcreci<\/strong>\u2014herhangi bir kimlik belgesini y\u00fckleyin ve hemen i\u015flem yapmaya ba\u015flay\u0131n<\/li>\n<li><strong>100&#8217;den fazla para \u00e7ekme y\u00f6ntemi<\/strong>\u2014kripto paralardan e-c\u00fczdanlara ve banka kartlar\u0131na kadar<\/li>\n<li><strong>Kesirli hisse senetleri mevcut<\/strong>\u2014PCVX gibi pahal\u0131 hisselerin par\u00e7alar\u0131n\u0131 tam hisse almadan sat\u0131n al\u0131n<\/li>\n<\/ul>\n<p>Platformun d\u00fc\u015f\u00fck giri\u015f engeli, b\u00fcy\u00fck sermaye taahh\u00fcd\u00fc olmadan y\u00fcksek potansiyelli biyotek hisselerine maruz kalmak isteyen yeni ba\u015flayanlar i\u00e7in idealdir.<\/p>\n<h2>\ud83c\udf0d 2025&#8217;te Vaxcyte: A\u015f\u0131 \u0130novasyon Lideri<\/h2>\n<p>Vaxcyte, yeni nesil a\u015f\u0131 teknolojisinin \u00f6n saflar\u0131nda yer al\u0131yor. Kendi XpressCF\u2122 platformlar\u0131n\u0131 kullanarak, bakteriyel enfeksiyonlar\u0131 \u00f6nlemede devrim yaratabilecek konjuge a\u015f\u0131lar geli\u015ftiriyorlar <a href=\"https:\/\/stockanalysis.com\/stocks\/pcvx\/company\/\">StockAnalysis<\/a>.<\/p>\n<p>\u015eirketin \u00f6nc\u00fc aday\u0131 VAX-24, 24 pn\u00f6mokok bakteri su\u015funu hedeflerken, VAX-31 bunu 31 su\u015fa geni\u015fletiyor\u2014mevcut a\u015f\u0131lardan daha geni\u015f koruma sunma potansiyeline sahip. 414 \u00e7al\u0131\u015fan\u0131 ve Kaliforniya, San Carlos&#8217;taki genel merkezi ile Vaxcyte, Amerikan inovasyonunun en iyisini temsil ediyor.<\/p>\n<p><strong>\u0130lgin\u00e7 Bilgi<\/strong>: 2025&#8217;te Vaxcyte&#8217;nin FDA At\u0131l\u0131m Tedavisi tan\u0131m\u0131, zat\u00fcrre \u00f6nlemeyi de kapsayacak \u015fekilde geni\u015fletildi\u2014bu, VAX-31 a\u015f\u0131 adaylar\u0131n\u0131n potansiyel \u00f6nemini vurgulayan nadir bir d\u00fczenleyici ba\u015far\u0131d\u0131r <a href=\"https:\/\/www.stocktitan.net\/news\/PCVX\/vaxcyte-reports-second-quarter-2025-financial-results-and-provides-9l3y1y5unk80.html\">StockTitan<\/a>. Bu, onlar\u0131 biyoteknoloji yenilik\u00e7ileri aras\u0131nda se\u00e7kin bir konuma yerle\u015ftiriyor.<\/p>\n"},"faq":[{"question":"Vaxcyte hisseleri nereden al\u0131nabilir?","answer":"Vaxcyte hisseleri NASDAQ borsas\u0131nda PCVX sembol\u00fc ile i\u015flem g\u00f6rmektedir. G\u00fcvenilir bir arac\u0131 kurum veya online ticaret platformu \u00fczerinden sat\u0131n alabilirsiniz."},{"question":"Vaxcyte'nin klinik a\u015fama riski nedir?","answer":"Klinik a\u015fama \u015firketlerde deneme sonu\u00e7lar\u0131 belirsiz olabilir ve ba\u015far\u0131s\u0131zl\u0131k riski y\u00fcksektir. Vaxcyte'nin May\u0131s 2025'te ya\u015fad\u0131\u011f\u0131 %45'lik fiyat d\u00fc\u015f\u00fc\u015f\u00fc bu riski g\u00f6stermektedir."},{"question":"Vaxcyte hisseleri i\u00e7in fiyat tahmini nedir?","answer":"Analistlerin ortalama fiyat hedefi 2030 y\u0131l\u0131na kadar 180-220 $ aral\u0131\u011f\u0131nda olup, mevcut fiyatlara g\u00f6re \u00f6nemli bir y\u00fckseli\u015f potansiyeli g\u00f6stermektedir."},{"question":"Yat\u0131r\u0131m yaparken nelere dikkat etmeliyim?","answer":"D\u00fczenli k\u00fc\u00e7\u00fck yat\u0131r\u0131mlar yaparak dolar-maliyet ortalamas\u0131 uygulamak, stop-loss emirleri koymak ve portf\u00f6y\u00fcn\u00fcz\u00fc \u00e7e\u015fitlendirmek \u00f6nemlidir."},{"question":"Pocket Option yeni yat\u0131r\u0131mc\u0131lar i\u00e7in neden uygundur?","answer":"D\u00fc\u015f\u00fck minimum depozito, h\u0131zl\u0131 KYC s\u00fcreci, \u00e7ok say\u0131da para \u00e7ekme y\u00f6ntemi ve kesirli hisse al\u0131m imkan\u0131 sunmas\u0131 nedeniyle yeni ba\u015flayanlar i\u00e7in idealdir."}],"faq_source":{"label":"FAQ","type":"repeater","formatted_value":[{"question":"Vaxcyte hisseleri nereden al\u0131nabilir?","answer":"Vaxcyte hisseleri NASDAQ borsas\u0131nda PCVX sembol\u00fc ile i\u015flem g\u00f6rmektedir. G\u00fcvenilir bir arac\u0131 kurum veya online ticaret platformu \u00fczerinden sat\u0131n alabilirsiniz."},{"question":"Vaxcyte'nin klinik a\u015fama riski nedir?","answer":"Klinik a\u015fama \u015firketlerde deneme sonu\u00e7lar\u0131 belirsiz olabilir ve ba\u015far\u0131s\u0131zl\u0131k riski y\u00fcksektir. Vaxcyte'nin May\u0131s 2025'te ya\u015fad\u0131\u011f\u0131 %45'lik fiyat d\u00fc\u015f\u00fc\u015f\u00fc bu riski g\u00f6stermektedir."},{"question":"Vaxcyte hisseleri i\u00e7in fiyat tahmini nedir?","answer":"Analistlerin ortalama fiyat hedefi 2030 y\u0131l\u0131na kadar 180-220 $ aral\u0131\u011f\u0131nda olup, mevcut fiyatlara g\u00f6re \u00f6nemli bir y\u00fckseli\u015f potansiyeli g\u00f6stermektedir."},{"question":"Yat\u0131r\u0131m yaparken nelere dikkat etmeliyim?","answer":"D\u00fczenli k\u00fc\u00e7\u00fck yat\u0131r\u0131mlar yaparak dolar-maliyet ortalamas\u0131 uygulamak, stop-loss emirleri koymak ve portf\u00f6y\u00fcn\u00fcz\u00fc \u00e7e\u015fitlendirmek \u00f6nemlidir."},{"question":"Pocket Option yeni yat\u0131r\u0131mc\u0131lar i\u00e7in neden uygundur?","answer":"D\u00fc\u015f\u00fck minimum depozito, h\u0131zl\u0131 KYC s\u00fcreci, \u00e7ok say\u0131da para \u00e7ekme y\u00f6ntemi ve kesirli hisse al\u0131m imkan\u0131 sunmas\u0131 nedeniyle yeni ba\u015flayanlar i\u00e7in idealdir."}]}},"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v24.8 (Yoast SEO v27.2) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Vaxcyte, Inc. (PCVX) Hisseleri Nas\u0131l Al\u0131n\u0131r - Vaxcyte, Inc. (PCVX) Hisse Senedi Yat\u0131r\u0131m\u0131<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-vaxcyte\/\" \/>\n<meta property=\"og:locale\" content=\"tr_TR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Vaxcyte, Inc. (PCVX) Hisseleri Nas\u0131l Al\u0131n\u0131r - Vaxcyte, Inc. (PCVX) Hisse Senedi Yat\u0131r\u0131m\u0131\" \/>\n<meta property=\"og:description\" content=\"text\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-vaxcyte\/\" \/>\n<meta property=\"og:site_name\" content=\"Pocket Option blog\" \/>\n<meta property=\"article:published_time\" content=\"2025-08-29T06:15:54+00:00\" \/>\n<meta name=\"author\" content=\"Signal\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Yazan:\" \/>\n\t<meta name=\"twitter:data1\" content=\"Signal\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-vaxcyte\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-vaxcyte\/\"},\"author\":{\"name\":\"Signal\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\"},\"headline\":\"Vaxcyte, Inc. (PCVX) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Vaxcyte, Inc. (PCVX) Hisse Senedi Yat\u0131r\u0131m\u0131\",\"datePublished\":\"2025-08-29T06:15:54+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-vaxcyte\/\"},\"wordCount\":19,\"commentCount\":0,\"image\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-vaxcyte\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals5.webp\",\"keywords\":[\"signal\"],\"articleSection\":[\"Signals\"],\"inLanguage\":\"tr\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-vaxcyte\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-vaxcyte\/\",\"url\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-vaxcyte\/\",\"name\":\"Vaxcyte, Inc. (PCVX) Hisseleri Nas\u0131l Al\u0131n\u0131r - Vaxcyte, Inc. (PCVX) Hisse Senedi Yat\u0131r\u0131m\u0131\",\"isPartOf\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-vaxcyte\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-vaxcyte\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals5.webp\",\"datePublished\":\"2025-08-29T06:15:54+00:00\",\"author\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\"},\"breadcrumb\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-vaxcyte\/#breadcrumb\"},\"inLanguage\":\"tr\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-vaxcyte\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"tr\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-vaxcyte\/#primaryimage\",\"url\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals5.webp\",\"contentUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals5.webp\",\"width\":1408,\"height\":768},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-vaxcyte\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/pocketoption.com\/blog\/tr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Vaxcyte, Inc. (PCVX) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Vaxcyte, Inc. (PCVX) Hisse Senedi Yat\u0131r\u0131m\u0131\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#website\",\"url\":\"https:\/\/pocketoption.com\/blog\/tr\/\",\"name\":\"Pocket Option blog\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/pocketoption.com\/blog\/tr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"tr\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\",\"name\":\"Signal\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"tr\",\"@id\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"caption\":\"Signal\"},\"url\":\"https:\/\/pocketoption.com\/blog\/tr\/author\/signal\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Vaxcyte, Inc. (PCVX) Hisseleri Nas\u0131l Al\u0131n\u0131r - Vaxcyte, Inc. (PCVX) Hisse Senedi Yat\u0131r\u0131m\u0131","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-vaxcyte\/","og_locale":"tr_TR","og_type":"article","og_title":"Vaxcyte, Inc. (PCVX) Hisseleri Nas\u0131l Al\u0131n\u0131r - Vaxcyte, Inc. (PCVX) Hisse Senedi Yat\u0131r\u0131m\u0131","og_description":"text","og_url":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-vaxcyte\/","og_site_name":"Pocket Option blog","article_published_time":"2025-08-29T06:15:54+00:00","author":"Signal","twitter_card":"summary_large_image","twitter_misc":{"Yazan:":"Signal"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-vaxcyte\/#article","isPartOf":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-vaxcyte\/"},"author":{"name":"Signal","@id":"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe"},"headline":"Vaxcyte, Inc. (PCVX) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Vaxcyte, Inc. (PCVX) Hisse Senedi Yat\u0131r\u0131m\u0131","datePublished":"2025-08-29T06:15:54+00:00","mainEntityOfPage":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-vaxcyte\/"},"wordCount":19,"commentCount":0,"image":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-vaxcyte\/#primaryimage"},"thumbnailUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals5.webp","keywords":["signal"],"articleSection":["Signals"],"inLanguage":"tr","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-vaxcyte\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-vaxcyte\/","url":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-vaxcyte\/","name":"Vaxcyte, Inc. (PCVX) Hisseleri Nas\u0131l Al\u0131n\u0131r - Vaxcyte, Inc. (PCVX) Hisse Senedi Yat\u0131r\u0131m\u0131","isPartOf":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-vaxcyte\/#primaryimage"},"image":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-vaxcyte\/#primaryimage"},"thumbnailUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals5.webp","datePublished":"2025-08-29T06:15:54+00:00","author":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe"},"breadcrumb":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-vaxcyte\/#breadcrumb"},"inLanguage":"tr","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-vaxcyte\/"]}]},{"@type":"ImageObject","inLanguage":"tr","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-vaxcyte\/#primaryimage","url":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals5.webp","contentUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals5.webp","width":1408,"height":768},{"@type":"BreadcrumbList","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-vaxcyte\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/pocketoption.com\/blog\/tr\/"},{"@type":"ListItem","position":2,"name":"Vaxcyte, Inc. (PCVX) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Vaxcyte, Inc. (PCVX) Hisse Senedi Yat\u0131r\u0131m\u0131"}]},{"@type":"WebSite","@id":"https:\/\/pocketoption.com\/blog\/tr\/#website","url":"https:\/\/pocketoption.com\/blog\/tr\/","name":"Pocket Option blog","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pocketoption.com\/blog\/tr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"tr"},{"@type":"Person","@id":"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe","name":"Signal","image":{"@type":"ImageObject","inLanguage":"tr","@id":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","caption":"Signal"},"url":"https:\/\/pocketoption.com\/blog\/tr\/author\/signal\/"}]}},"po_author":null,"po__editor":null,"po_last_edited":null,"wpml_current_locale":"tr_TR","wpml_translations":{"vt_VT":{"locale":"vt_VT","id":356331,"slug":"how-to-buy-vaxcyte","post_title":"C\u00e1ch mua c\u1ed5 phi\u1ebfu Vaxcyte, Inc. (PCVX) - \u0110\u1ea7u t\u01b0 v\u00e0o c\u1ed5 phi\u1ebfu Vaxcyte, Inc. (PCVX)","href":"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-vaxcyte\/"},"pt_AA":{"locale":"pt_AA","id":356328,"slug":"how-to-buy-vaxcyte","post_title":"Como comprar a\u00e7\u00f5es da Vaxcyte, Inc. (PCVX) - Investimento em a\u00e7\u00f5es da Vaxcyte, Inc. (PCVX)","href":"https:\/\/pocketoption.com\/blog\/pt\/news-events\/signal\/how-to-buy-vaxcyte\/"}},"_links":{"self":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/posts\/356329","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/users\/129"}],"replies":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/comments?post=356329"}],"version-history":[{"count":0,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/posts\/356329\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/media\/334027"}],"wp:attachment":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/media?parent=356329"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/categories?post=356329"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/tags?post=356329"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}